-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
MediPharm Labs Enters Into $4.68M Purchase Agreement For The Sale Of Australian Facility
MediPharm Labs Enters Into $4.68M Purchase Agreement For The Sale Of Australian Facility
MediPharm Labs Corp. (OTCQX:MEDIF) (TSX:LABS) (FSE:MLZ) a pharmaceutical company specialized in precision-based cannabinoids, has entered into a share prchase agreement with OneLife Botanicals PTY for the sale of MediPharm Labs Australia Pty Ltd, a wholly-owned subsidiary of the company, for a minimum value of AU$6.9 million ($4.68 million). The agreement is subject to routine conditions and is anticipated to close within 90 days.
The agreement includes the assets of MPLA, specialized licensing, operational knowledge, and Australian and New Zealand customers currently served from that facility. All international contracts outside of Australia and New Zealand will remain with MediPharm Labs and be serviced from our Barrie GMP facility.
In July 2021, MediPharm Labs was the first purpose-built cannabis facility to receive a pharmaceutical Drug Establishment License. Awarded by Health Canada, this license is recognized in over 50 countries as part of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). At this time, the company has completed a review of its international manufacturing platform and identified significant potential savings in moving all domestic and international manufacturing to the Canadian facility.
After an extensive sale process, the agreement with OneLife Botanicals was identified as a strategic fit for both parties. OneLife Botanicals is an emerging leader in Australia region for cannabis-based wellness and medical products, with plans to launch OTC CBD products across Australia. Purchasing the MPLA facility expedites OneLife Botanicals' timing to commercialization. The company and OneLife Botanicals will also enter into a transition services agreement to allow for the two companies to smoothly transition products and services produced in the facility, and to work together on future commercial opportunities.
David Pidduck, CEO of MediPharm Labs stated, "This sale represents a major milestone for MediPharm Labs as it continues to focus on rightsizing the business to achieve profitability. As we look to maintain our strong cash balance, this transaction paired with corporate restructuring completed in June 2022 should allow us to reduce our quarterly burn rate as we improve sales.
I want to personally thank our Australian team. This group of professionals are trailblazers in the Australian and international medical cannabis market, achieving major milestones such as multiple customer product launches and our first deliveries to Germany. OneLife Botanicals is gaining one of the most capable medical cannabis manufacturing teams in Australia."
Photo by Richard T on Unsplash
Related News
BREAKING: Brazil Supreme Court Authorizes Citizens To Grow Medicinal Cannabis
MediPharm Labs Q1 Revenue Slightly Drops, Here Are The Details
MediPharm Labs Launches CBG And Water-Soluble CBN:THC Products
MediPharm Labs Corp. (OTCQX:MEDIF) (TSX:LABS) (FSE:MLZ) a pharmaceutical company specialized in precision-based cannabinoids, has entered into a share prchase agreement with OneLife Botanicals PTY for the sale of MediPharm Labs Australia Pty Ltd, a wholly-owned subsidiary of the company, for a minimum value of AU$6.9 million ($4.68 million). The agreement is subject to routine conditions and is anticipated to close within 90 days.
医疗药业实验室公司(多伦多证券交易所股票代码:MEDIF)(多伦多证券交易所股票代码:LABS)(多伦多证券交易所股票代码:MLZ)是一家专门生产精密大麻类药物的制药公司,该公司已与s野兔pRChasea与OneLife Botanals Pty达成协议对于销售的澳大利亚医药实验室私人有限公司,该公司的全资附属公司,最低价值为Au(自动)$6.9 百万(468万美元)。该协议受到例行条件的限制,预计将在90天内完成。
The agreement includes the assets of MPLA, specialized licensing, operational knowledge, and Australian and New Zealand customers currently served from that facility. All international contracts outside of Australia and New Zealand will remain with MediPharm Labs and be serviced from our Barrie GMP facility.
该协议包括M解放军的资产、专业许可、运营知识以及目前由该设施提供服务的澳大利亚和新西兰客户。澳大利亚和新西兰以外的所有国际合同都将保留在医疗制药实验室,并由我们的巴里GMP设施提供服务。
In July 2021, MediPharm Labs was the first purpose-built cannabis facility to receive a pharmaceutical Drug Establishment License. Awarded by Health Canada, this license is recognized in over 50 countries as part of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). At this time, the company has completed a review of its international manufacturing platform and identified significant potential savings in moving all domestic and international manufacturing to the Canadian facility.
2021年7月,MediPharm实验室成为第一个接受药物治疗的专门建造的大麻设施《药品经营许可证》。由加拿大卫生部颁发,这一许可证在50多个国家和地区被公认为药检合作计划(图片S)。目前,该公司已经完成了对其国际制造平台的审查,并确定了将所有国内和国际制造转移到加拿大工厂的显著节省潜力。
After an extensive sale process, the agreement with OneLife Botanicals was identified as a strategic fit for both parties. OneLife Botanicals is an emerging leader in Australia region for cannabis-based wellness and medical products, with plans to launch OTC CBD products across Australia. Purchasing the MPLA facility expedites OneLife Botanicals' timing to commercialization. The company and OneLife Botanicals will also enter into a transition services agreement to allow for the two companies to smoothly transition products and services produced in the facility, and to work together on future commercial opportunities.
经过广泛的销售过程,与OneLife Botanals的协议被确定为双方的战略合适人选。OneLife Botanals是澳大利亚地区大麻保健和医疗产品的新兴领先者,计划推出澳大利亚的场外CBD产品。购买MPLA设施加快了OneLife Botanals商业化的时机。该公司和OneLife Botanals还将签订一项过渡服务协议,使两家公司能够顺利过渡该设施生产的产品和服务,并就未来的商业机会进行合作。
David Pidduck, CEO of MediPharm Labs stated, "This sale represents a major milestone for MediPharm Labs as it continues to focus on rightsizing the business to achieve profitability. As we look to maintain our strong cash balance, this transaction paired with corporate restructuring completed in June 2022 should allow us to reduce our quarterly burn rate as we improve sales.
大卫·皮达克,医药实验室首席执行官表示:“此次出售对医药实验室来说是一个重要的里程碑,因为该实验室将继续专注于调整业务以实现盈利。在我们寻求保持强大的现金平衡的同时,这笔交易与2022年6月完成的公司重组相结合,将使我们能够在提高销售额的同时降低季度烧损率。
I want to personally thank our Australian team. This group of professionals are trailblazers in the Australian and international medical cannabis market, achieving major milestones such as multiple customer product launches and our first deliveries to Germany. OneLife Botanicals is gaining one of the most capable medical cannabis manufacturing teams in Australia."
我想亲自感谢我们的澳大利亚队。这群专业人士是澳大利亚和国际医用大麻市场的开拓者,实现了重大里程碑,如推出多个客户的产品和我们向德国的第一批交货。OneLife Botanals正在获得澳大利亚最有能力的医用大麻制造团队之一。
Photo by Richard T on Unsplash
理查德·T在Unspash上的照片
Related News
相关新闻
BREAKING: Brazil Supreme Court Authorizes Citizens To Grow Medicinal Cannabis
突破:巴西最高法院授权公民种植药用大麻
MediPharm Labs Q1 Revenue Slightly Drops, Here Are The Details
医药实验室第一季度收入略有下降,以下是详细信息
MediPharm Labs Launches CBG And Water-Soluble CBN:THC Products
梅迪帕姆实验室推出CBG和水溶性CBN:THC产品
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧